{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:24:51Z","timestamp":1787808291892,"version":"build-2784847793"},"reference-count":51,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,8]]},"abstract":"<jats:p>\n                    Subarachnoid neurocysticercosis (SUBNCC) is usually caused by an aberrant proliferative form of\n                    <jats:italic>Taenia solium<\/jats:italic>\n                    causing mass effect and arachnoiditis. Thirty of 34 SUBNCC patients were treated with extended cysticidal and anti-inflammatory regimens and followed up a median of 4.2 years posttreatment (range: 15 for \u2265 4 years, 20 \u2265 2 years, 26 &gt; 1 year, and 3 &lt; 1 year). The median ages at the time of first symptom, diagnosis, and enrollment were 29.7, 35.6, and 37.9 years, respectively; 58.8% were male and 82.4% were Hispanic. The median time from immigration to symptoms (minimum incubation) was 10 years and the estimated true incubation period considerably greater. Fifty percent also had other forms of NCC. Common complications were hydrocephalus (56%), shunt placement (41%), infarcts (18%), and symptomatic spinal disease (15%). Thirty patients (88.2%) required prolonged treatment with albendazole (88.2%, median 0.55 year) and\/or praziquantel (61.8%; median 0.96 year), corticosteroids (88.2%, median 1.09 years), methotrexate (50%, median 1.37 years), and etanercept (34.2%, median 0.81 year), which led to sustained inactive disease in 29\/30 (96.7%) patients. Three were treated successfully for recurrences and one has continuing infection. Normalization of cerebral spinal fluid parameters and cestode antigen levels guided treatment decisions. All 15 patients with undetectable cestode antigen values have sustained inactive disease. There were no deaths and moderate morbidity posttreatment. Corticosteroid-related side effects were common, avascular necrosis of joints being the most serious (8\/33, 24.2%). Prolonged cysticidal treatment and effective control of inflammation led to good clinical outcomes and sustained inactive disease which is likely curative.\n                  <\/jats:p>","DOI":"10.4269\/ajtmh.19-0436","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T03:01:04Z","timestamp":1571713264000},"page":"78-89","source":"Crossref","is-referenced-by-count":72,"title":["Natural History of Treated Subarachnoid Neurocysticercosis"],"prefix":"10.4269","volume":"102","author":[{"given":"Theodore E.","family":"Nash","sequence":"first","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima A.","family":"Hammoud","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Imaging, Clinical Center, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wetzler","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JeanAnne M.","family":"Ware","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Mahanty","sequence":"additional","affiliation":[{"name":"Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","series-title":"Lancet Neurol","first-page":"1202","article-title":"Clinical symptoms, diagnosis, and treatment of neurocysticercosis","volume":"13","author":"Garcia","year":"2014"},{"key":"b2","series-title":"Brain Pathol","first-page":"681","article-title":"Neurocysticercosis","volume":"7","author":"Pittella","year":"1997"},{"key":"b3","series-title":"Handbuch der Neurologie","first-page":"643","article-title":"Die tierischen parasiten des zentralnerven-systems","author":"Henneberg","year":"1912"},{"key":"b4","series-title":"Folia Parasitol (Praha)","first-page":"207","article-title":"Histochemistry of the racemose form of Cysticercus cellulosae","volume":"39","author":"Valkounova","year":"1992"},{"key":"b5","series-title":"Neuropathology of Parasitic Infections","author":"Brown","year":"1982"},{"key":"b6","series-title":"Cysticercosis of the Central Nervous System","first-page":"27","article-title":"Pathology of the nervous system","author":"Escobar","year":"1983"},{"key":"b7","series-title":"Pathology of Protozoal and Hleminthic Diseases","first-page":"592","article-title":"Cysticercosis","author":"Marquez-Monter","year":"1971"},{"key":"b8","series-title":"Beitr Anat Embryolo J Henle Festg","first-page":"119","article-title":"Ueber den Cysticercus racemosus des Gehirns","author":"Zenker","year":"1882"},{"key":"b9","series-title":"J Neuroimaging","first-page":"38","article-title":"Extraparenchymal neurocysticercosis in Albuquerque, New Mexico","volume":"21","author":"Figueroa","year":"2011"},{"key":"b10","series-title":"PLoS Negl Trop Dis","first-page":"e0005115","article-title":"Clinical symptoms, imaging features and cyst distribution in the cerebrospinal fluid compartments in patients with extraparenchymal neurocysticercosis","volume":"10","author":"Bazan","year":"2016"},{"key":"b11","series-title":"Plos Negl Trop Dis","first-page":"e0005646","article-title":"Extraparenchymal neurocysticercosis: demographic, clinicoradiological, and inflammatory features","volume":"11","author":"Sierra","year":"2017"},{"key":"b12","series-title":"Medicine (Baltimore)","first-page":"81","article-title":"Neurocysticercosis in Houston, Texas: an update","volume":"90","author":"Serpa","year":"2011"},{"key":"b13","series-title":"Infectious Diseases of the Central Nervous System","author":"Greenfield","year":"1958"},{"key":"b14","series-title":"Trans R Soc Trop Med Hyg","first-page":"377","article-title":"Neurocysticercosis: treatment with albendazole and dextrochloropheniramine","volume":"83","author":"Agapejev","year":"1989"},{"key":"b15","series-title":"Neurology","first-page":"177","article-title":"Proposed diagnostic criteria for neurocysticercosis","volume":"57","author":"Del Brutto","year":"2001"},{"key":"b16","series-title":"Clin Infect Dis","first-page":"549","article-title":"Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis","volume":"44","author":"Mitre","year":"2007"},{"key":"b17","series-title":"Am J Trop Med Hyg","first-page":"609","article-title":"Etanercept to control inflammation in the treatment of complicated neurocysticercosis","volume":"100","author":"Nash","year":"2019"},{"key":"b18","series-title":"Am J Trop Med Hyg","first-page":"1755","article-title":"Intraventricular neurocysticercosis: experience and long-term outcome from a tertiary referral center in the United States","volume":"98","author":"Nash","year":"2018"},{"key":"b19","series-title":"Am J Trop Med Hyg","first-page":"919","article-title":"Corticosteroid withdrawal precipitates perilesional edema around calcified Taenia solium cysts","volume":"89","author":"Mejia","year":"2013"},{"key":"b20","series-title":"Cysticercosis: An Analysis and Follow up of 450 Cases","first-page":"1","author":"Dixon","year":"1961"},{"key":"b21","series-title":"J Trav Med","first-page":"112","article-title":"Neurocysticercosis among international travelers to disease-endemic areas","volume":"19","author":"Del Brutto","year":"2012"},{"key":"b22","series-title":"J Neurol Neurosurg Psychiatry","first-page":"252","article-title":"Cysticercosis and cerebrovascular disease: a review","volume":"55","author":"Del Brutto","year":"1992"},{"key":"b23","series-title":"Br Med J","first-page":"1055","article-title":"Cerebral cysticercosis: common but unfamiliar manifestations","volume":"1","author":"Bickerstaff","year":"1955"},{"key":"b24","series-title":"Neurology","first-page":"1078","article-title":"Carotid occlusion in cysticercosis","volume":"33","author":"McCormick","year":"1983"},{"key":"b25","series-title":"Ann Neurol","first-page":"161","article-title":"Clinicopathology conference: 41-year-old woman with chronic relapsing meningitis","volume":"85","author":"Beck","year":"2019"},{"key":"b26","series-title":"Neurology","first-page":"1394","article-title":"High frequency of spinal involvement in patients with basal subarachnoid neurocysticercosis","volume":"78","author":"Callacondo","year":"2012"},{"key":"b27","series-title":"Arq Neuropsiquiatr","first-page":"82","article-title":"Severe forms of neurocysticercosis: treatment with albendazole","volume":"54","author":"Agapejev","year":"1996"},{"key":"b28","series-title":"J Neurol","first-page":"15","article-title":"Active neurocysticercosis, parenchymal and extraparenchymal: a study of 38 patients","volume":"241","author":"Monteiro","year":"1993"},{"key":"b29","series-title":"J Neurol Neurosurg Psychiatry","first-page":"659","article-title":"Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients","volume":"62","author":"Del Brutto","year":"1997"},{"key":"b30","series-title":"BMC Neurol","first-page":"16","article-title":"Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: a case series","volume":"10","author":"Cardenas","year":"2010"},{"key":"b31","series-title":"Neurology","first-page":"436","article-title":"Albendazole trial at 15 or 30 mg\/kg\/day for subarachnoid and intraventricular cysticercosis","volume":"66","author":"Gongora-Rivera","year":"2006"},{"key":"b32","series-title":"Arch Neurol","first-page":"535","article-title":"Albendazole therapy for giant subarachnoid cysticerci","volume":"49","author":"Del Brutto","year":"1992"},{"key":"b33","series-title":"J Clin Pharmacol","first-page":"548","article-title":"Factors associated with cysticidal treatment response in extraparenchymal neurocysticercosis","volume":"59","author":"Osorio","year":"2019"},{"key":"b34","series-title":"Expert Rev Anti Infect Ther","first-page":"123","article-title":"Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease","volume":"9","author":"Fleury","year":"2011"},{"key":"b35","series-title":"N Engl J Med","first-page":"879","article-title":"Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts","volume":"345","author":"Proano","year":"2001"},{"key":"b36","series-title":"Archiv f\u00fcr pathologische Anatomie Physiologie klinische Medicin","first-page":"528","article-title":"Traubenhydatiden der weichen hirnhaut","volume":"18","author":"Virchow","year":"1860"},{"key":"b37","series-title":"Tropical Neurology","first-page":"162","article-title":"Histopathology of cerebral cysticercosis","author":"Trelles","year":"1961"},{"key":"b38","series-title":"N Engl J Med","first-page":"1924","article-title":"Case 15-2012: a 48-year-old woman with diplopia, headaches, and papilledema","volume":"366","author":"Venna","year":"2012"},{"key":"b39","series-title":"Expert Rev Neurother","first-page":"1175","article-title":"Corticosteroid use in neurocysticercosis","volume":"11","author":"Nash","year":"2011"},{"key":"b40","series-title":"Clin Infect Dis","first-page":"e49","article-title":"Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"66","author":"White","year":"2018"},{"key":"b41","series-title":"Neurologist","first-page":"17","article-title":"Cerebrovascular complications of neurocysticercosis","volume":"18","author":"Marquez","year":"2012"},{"key":"b42","series-title":"Stroke","first-page":"123","article-title":"Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study","volume":"29","author":"Barinagarrementeria","year":"1998"},{"key":"b43","series-title":"Arch Neurol","first-page":"415","article-title":"Lacunar syndrome due to neurocysticercosis","volume":"46","author":"Barinagarrementeria","year":"1989"},{"key":"b44","series-title":"Arch Neurol","first-page":"233","article-title":"Cerebrovascular complications of neurocysticercosis: clinical and neuroimaging spectrum","volume":"53","author":"Cantu","year":"1996"},{"key":"b45","series-title":"Lancet Infect Dis","first-page":"266","article-title":"Combined antiparasitic treatment for neurocysticercosis [reply]","volume":"15","author":"Garcia","year":"2015"},{"key":"b46","series-title":"Plos Negl Trop Dis","first-page":"e2096","article-title":"Neurocysticercosis: HP10 antigen detection is useful for the follow-up of the severe patients","volume":"7","author":"Fleury","year":"2013"},{"key":"b47","series-title":"J Neurol Neurosurg Psychiatry","first-page":"970","article-title":"Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis","volume":"78","author":"Fleury","year":"2007"},{"key":"b48","series-title":"J Neuroparasitol","first-page":"1","article-title":"Antigen levels follow post-treatment evolution of subarachnoid neurocysticercosis","volume":"1","author":"Garcia","year":"2010"},{"key":"b49","series-title":"Am J Trop Med Hyg","first-page":"1305","article-title":"Successful antiparasitic treatment for cysticercosis is associated with a fast and marked reduction of circulating antigen levels in a naturally infected pig model","volume":"93","author":"Gonzalez","year":"2015"},{"key":"b50","series-title":"Trop Med Int Health","first-page":"943","article-title":"Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow-up","volume":"11","author":"Bobes","year":"2006"},{"key":"b51","series-title":"Antimicrob Agents Chemother","first-page":"211","article-title":"Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts","volume":"55","author":"Mahanty","year":"2011"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/1\/article-p78.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/1\/article-p78.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/102\/1\/article-p78.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:56:29Z","timestamp":1722448589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/102\/1\/article-p78.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":51,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.19-0436","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736795939.793571515","asserted-by":"object"}]},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]}}}